Alzinova has recently filed a new patent application for a further developed form of the Company's monoclonal antibody ALZ-201. If the Company receives approval of the patent, the expected patent term would extend to at least 2044. Alzinova is continuously working on its intellectual property strategy and the application is an important part of the further development of the patent portfolio for the Company's pharmaceutical candidates.

"The patent strategy and application are important parts of our efforts to position Alzinova as a leading actor in the development of treatments for Alzheimer's disease. We work continuously to strengthen our patent portfolio, which is also essential for future partner discussions", comments CEO Kristina Torfgård.

More about ALZ-201
ALZ-201 is a monoclonal antibody developed to specifically target and neutralize the toxic forms of the peptide amyloid-beta-42 ("Aβ42"), so-called oligomers, which are considered to be the underlying cause of Alzheimer's disease. The ALZ-201 antibody does not bind to other, harmless, forms of amyloid-beta such as fibrils and plaques as proven in pre-clinical studies on human material. The pre-clinical results indicate that it is a small amount of Aβ42 oligomers that account for the main toxic effect in Alzheimer's disease, and that specificity for this form is probably necessary to obtain a good therapeutic effect of an antibody treatment. Alzinova is currently developing a humanized version of ALZ-201 for Phase 1 clinical trials in patients with Alzheimer's disease. These studies are planned to start in 2024. The Company's research shows that both ALZ-201 and the vaccine ALZ-101 have best-in-class potential, and clinical results from other players in the field support the Company's strategy.